Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Athina Trachalaki, Nadiya Sultana & Athol Umfrey Wells. (2023) An update on current and emerging drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Pharmacotherapy 24:10, pages 1125-1142.
Read now
Read now
Athina Trachalaki, Mujammil Irfan & Athol U Wells. (2021) Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opinion on Pharmacotherapy 22:2, pages 191-204.
Read now
Read now
Swati Gulati & Tracy R Luckhardt. (2020) Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis. Drug, Healthcare and Patient Safety 12, pages 85-94.
Read now
Read now
Articles from other publishers (18)
Arianna Traunero, Francesca Peri, Laura Badina, Alessandro Amaddeo, Elettra Zuliani, Massimo Maschio, Egidio Barbi & Sergio Ghirardo. (2023) Hematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview. Children 10:9, pages 1535.
Crossref
Crossref
Jiwon Kim, Chiwook Chung, Hyo Sin Cho & Ho Cheol Kim. (2023) Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data. PLOS ONE 18:2, pages e0281295.
Crossref
Crossref
Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal & Jin Woo Song. (2023) Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Frontiers in Pharmacology 13.
Crossref
Crossref
Ondřej Májek, Jakub Gregor, Nesrin Mogulkoć, Katarzyna Lewandowska, Martina Šterclová, Veronika Müller, Marta Hájková, Mordechai R. Kramer, Jasna Tekavec-Trkanjec, Dragana Jovanović, Michael Studnicka, Natalia Stoeva, Klaus-Uwe Kirchgässler, Simona Littnerová, Ladislav Dušek & Martina Koziar Vašáková. (2022) Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLOS ONE 17:9, pages e0273854.
Crossref
Crossref
Leticia Kawano-Dourado, Marilyn K. Glassberg, Deborah Assayag, Raphaël Borie & Kerri A. Johannson. (2021) Sex and gender in interstitial lung diseases. European Respiratory Review 30:162, pages 210105.
Crossref
Crossref
Shu Hisata, Masashi Bando, Sakae Homma, Kensuke Kataoka, Takashi Ogura, Shinyu Izumi, Susumu Sakamoto, Kizuku Watanabe, Yoshinobu Saito, Yasuo Shimizu, Motoyasu Kato, Yasuhiko Nishioka, Hiromichi Hara, Yuko Waseda, Yoshinori Tanino, Kazuhiro Yatera, Seishu Hashimoto, Hiroshi Mukae & Naohiko Inase. (2021) Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory Investigation 59:6, pages 819-826.
Crossref
Crossref
Sebastian Majewski, Adam J. Białas, Małgorzata Buchczyk, Paweł Gomółka, Katarzyna Górska, Hanna Jagielska-Len, Agnieszka Jarzemska, Ewa Jassem, Dariusz Jastrzębski, Aleksander Kania, Marek Koprowski, Rafał Krenke, Jan Kuś, Katarzyna Lewandowska, Magdalena M. Martusewicz-Boros, Kazimierz Roszkowski-Śliż, Alicja Siemińska, Krzysztof Sładek, Małgorzata Sobiecka, Karolina Szewczyk, Małgorzata Tomczak, Witold Tomkowski, Elżbieta Wiatr, Dariusz Ziora, Beata Żołnowska & Wojciech J. Piotrowski. (2020) A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC Pulmonary Medicine 20:1.
Crossref
Crossref
Borja Marcos Ribes, José N Sancho-Chust, Amparo Talens, Mar Arlandis, Paola Herraiz, Eusebi Chiner & Teresa Aznar. (2020) Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. European Journal of Hospital Pharmacy 27:6, pages 350-354.
Crossref
Crossref
Jieun Kang, Minkyu Han & Jin Woo Song. (2020) Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Scientific Reports 10:1.
Crossref
Crossref
Deborah Assayag, Julie Morisset, Kerri A Johannson, Athol U Wells & Simon L F Walsh. (2020) Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax 75:5, pages 407-412.
Crossref
Crossref
Nupoor Acharya, Shefali Khanna Sharma, Debashish Mishra, Sahajal Dhooria, Varun Dhir & Sanjay Jain. (2020) Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. Rheumatology International 40:5, pages 703-710.
Crossref
Crossref
Monika Zurkova, Eva Kriegova, Vitezslav Kolek, Vladimira Lostakova, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Ilona Binkova, Michal Svoboda, Jana Strenkova, Marketa Janotova, Martina Plackova, Ladislav Lacina, Vladimir Rihak, Frantisek Petrik, Pavlina Lisa, Radka Bittenglova, Richard Tyl, Gustav Ondrejka, Hana Suldova, Jaroslav Lnenicka, Jana Psikalova, Tomas Snizek, Jiri Homolka, Renata Kralova, Jan Kervitzer & Martina Vasakova. (2019) Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respiratory Research 20:1.
Crossref
Crossref
Stefania Cerri, Matteo Monari, Aldo Guerrieri, Pierluigi Donatelli, Ilaria Bassi, Martina Garuti, Fabrizio Luppi, Sara Betti, Gianpiero Bandelli, Marco Carpano, Maria Letizia Bacchi Reggiani, Roberto Tonelli, Enrico Clini & Stefano Nava. (2019) Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respiratory Medicine 159, pages 105803.
Crossref
Crossref
Ismail Hanta, Aykut Cilli & Can Sevinc. (2019) The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study. Advances in Therapy 36:5, pages 1126-1131.
Crossref
Crossref
Vasilios Tzilas, Argyrios Tzouvelekis & Demosthenes Bouros. (2019) Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis. Respiration 98:1, pages 16-18.
Crossref
Crossref
Aurélien Justet, Gabriel Thabut, Effrosyni Manali, Maria Molina Molina, Caroline Kannengiesser, Jacques Cadranel, Vincent Cottin, Anne Gondouin, Hilario Nunes, Eline Magois, Cécile Tromeur, Grégoire Prevot, Spyros Papiris, Sylvain Marchand-Adam, Anne Sophie Gamez, Martine Reynaud-Gaubert, Lidwine Wemeau, Bruno Crestani & Raphael Borie. (2018) Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. European Respiratory Journal 51:3, pages 1701875.
Crossref
Crossref
Sergio Harari, Antonella Caminati, Venerino Poletti, Marco Confalonieri, Stefano Gasparini, Donato Lacedonia, Fabrizio Luppi, Alberto Pesci, Alfredo Sebastiani, Paolo Spagnolo, Carlo Vancheri, Elisabetta Balestro, Martina Bonifazi, Stefania Cerri, Federica De Giacomi, Rossana Della Porta, Maria Pia Foschino Barbaro, Annalisa Fui, Patrizio Pasquinelli, Roberta Rosso, Sara Tomassetti, Claudia Specchia & Paola Rottoli. (2018) A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. Respiration 95:6, pages 433-440.
Crossref
Crossref
Lisa H. Lancaster, Joao A. de Andrade, Joseph D. Zibrak, Maria L. Padilla, Carlo Albera, Steven D. Nathan, Marlies S. Wijsenbeek, John L. Stauffer, Klaus-Uwe Kirchgaessler & Ulrich Costabel. (2017) Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review 26:146, pages 170057.
Crossref
Crossref